A5111117449- Inflammatory Bowel Disease
- Microscopic Colitis
- Immunodeficiency and Autoimmune Disorders
- Pharmaceutical studies and practices
- Adolescent and Pediatric Healthcare
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders Research
- Digestive system and related health
- Advanced Causal Inference Techniques
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Gastrointestinal motility and disorders
- Liver Diseases and Immunity
- Intensive Care Unit Cognitive Disorders
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Celiac Disease Research and Management
- Iron Metabolism and Disorders
- Gut microbiota and health
- Transplantation: Methods and Outcomes
- Pregnancy and Medication Impact
- Intraperitoneal and Appendiceal Malignancies
- IL-33, ST2, and ILC Pathways
- Infant Health and Development
- Helicobacter pylori-related gastroenterology studies
Children's Hospital of Philadelphia
2014-2025
University of Pennsylvania
2017-2025
University Hospitals Cleveland Medical Center
2015
The pharmacokinetics of biologic agents can differ between children and adults with inflammatory bowel disease (IBD), often necessitating modified paediatric dosing strategies. To define the exposure-response relationship vedolizumab in IBD VedoKids cohort including effect baseline clearance on deep biochemical remission (normal C-reactive protein [CRP]/erythrocyte sedimentation rate [ESR] steroid-free remission) at 30 weeks, to use population pharmacokinetic models find best matches adult...
Vedolizumab is effective for inducing and maintaining remission in adults with inflammatory bowel disease (IBD); however, there limited pediatric data. This study aimed to describe the adverse events clinical response vedolizumab refractory IBD.Disease activity indices, response, concomitant medication use, were measured over 22 weeks an observational prospective cohort of children IBD who had failed anti-tumor necrosis factor therapy subsequently initiated therapy.Twenty-one subjects, 16...
Objectives: Colectomy rates following acute severe ulcerative colitis have plateaued around 20% despite intravenous corticosteroid and intensified anti-tumor necrosis factor (TNF) biologic dosing. Recent studies shown tofacitinib to provide additional benefit in further decreasing colectomy among hospitalized adult patients with corticosteroid- anti-TNF-nonresponsive colitis. Pediatric data describing the effectiveness of for this indication does not yet exist. We aimed describe treatment...
Abstract Background Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study describes the effectiveness and safety tofacitinib UC. Methods is a retrospective review children diagnosed with UC treated from 16 centers internationally. The primary outcome was week 8 corticosteroid-free clinical remission (Pediatric Ulcerative Colitis Activity Index <10). Secondary...
The impacts of missing data in comparative effectiveness research (CER) using electronic health records (EHRs) may vary depending on the type and pattern data. In this study, we aimed to quantify these compare performance different imputation methods.
Serum infliximab (s-IFX) levels, antibodies to IFX (ATI), and inflammatory markers are important in predicting clinical outcomes adults, but their roles pediatric Crohn's disease (CD) require further study. The primary aim of this study was determine the association between serologic parameters during induction ongoing therapy at 12 months CD. S-IFX, ATI, serum tumor necrosis factor alpha (s-TNF-α), C-reactive protein were measured initiation, 10 weeks, 6 months, a prospective cohort...
Tofacitinib, a selective Janus kinase inhibitor, effectively induces and maintains remission in adults with inflammatory bowel disease (IBD), but data are limited children. This study aimed to evaluate the efficacy safety of tofacitinib for medically refractory pediatric-onset IBD.This single-center retrospective included subjects ages 21 years younger who started IBD. Clinical activity indices, clinical response, steroid-free remission, biochemical adverse events (AEs) were evaluated over...
The authors declare no conflicts of interest.
Abstract Background Long-term data on the use of vedolizumab in children with Crohn’s disease (CD) and ulcerative colitis (UC) are lacking drug is not yet approved pediatrics. The VEDOKIDS prospective multicenter cohort study aimed to assess effectiveness safety as maintenance therapy CD UC; this reports 3-year final visit outcomes (ClinicalTrials.gov, NCT02862132). Methods Children commenced at any duration degree activity were enrolled 17 pediatric centers Europe, USA Middle East followed...
Importance The profile of gastrointestinal (GI) tract outcomes associated with the postacute and chronic phases COVID-19 in children adolescents remains unclear. Objective To investigate risks GI symptoms disorders during (28-179 days after documented SARS-CoV-2 infection) (180-729 pediatric population. Design, Setting, Participants This retrospective cohort study was performed from March 1, 2020, to September 2023, at 29 US health care institutions. included patients 18 years or younger...
Abstract Background Risankizumab (RISA) is a selective p19 anti-interleukin (IL)-23 antibody approved for adults with Crohn’s disease (CD) and children ≥ 16 years in selected countries. Given delays pediatric approvals, we aimed to assess the real-world effectiveness safety of RISA patients CD. Methods From September 2022 November 2023, all (<18 years) refractory CD treated 5 centers from US Israel were retrospectively included. All received 600 mg intravenous induction at weeks...
Summary Background Patients enrolled in randomised controlled trials (RCTs) may differ from the target population due to restricted eligibility criteria. Aim To compare treatment response biologics routine practice for children with inflammatory bowel diseases (IBD) who would and not have been eligible enrolment regulatory RCT of same drug. Methods We IBD initiated adalimumab, infliximab, vedolizumab or ustekinumab. The criteria as defined corresponding biologic were applied each patient....
Iron deficiency anemia (IDA) is a common complication of pediatric inflammatory bowel disease (IBD), yet the effectiveness oral iron supplementation limited. Intravenous sucrose an effective and safe alternative treatment for IDA in adults with IBD, but its role IBD unclear. The primary aim this study was to evaluate use subjects determine clinical response as measured by improvement hemoglobin concentration. secondary describe adverse events associated cohort.A retrospective chart review...
A 17-year-old female was admitted to our hospital with a 5-day history of fever (Tmax 38.5 o C), asthenia, and nausea, accompanied by right upper quadrant abdominal pain, back emesis, jaundice during the previous 24 hours. On physical exam at time presentation, she tall thin adolescent body mass index 14.5. She ill-appearing scleral icterus, scant shotty cervical lymphadenopathy, had an remarkable for tenderness palpation. no appreciable hepatosplenomegaly. The rest her unremarkable. Results...
Objectives: The primary aim of this study was to determine the proportion pediatric Crohn disease (CD) subjects in sustained drug‐free remission 52 weeks after stopping pharmacological therapy. We also aimed explore effects Disease Exclusion Diet (CDED) and microbiome composition on remission. Methods: performed a prospective following 18 CD patients ages 13–21 years deep clinical withdrawing from immunomodulator (n = 7) or anti‐TNFα 11) monotherapy at two tertiary care centers. Stool for...
Functional gastrointestinal disorders (FGIDs) are a common problem in pediatric patients and can affect quality of life. However, the extent these may vary different subpopulations children. This study investigated prevalence FGIDs an inner-city primary care practice. Healthy between ages 9 17 were administered validated questionnaire that assessed for other somatic complaints. Eleven 145 (7.5%) met criteria based on Rome III Diagnostic Criteria. Raynaud-like symptoms tended to occur more...
Iron deficiency anemia (IDA) is a common complication of pediatric inflammatory bowel disease (IBD). The effectiveness oral iron supplementation in the treatment IDA limited by its slow onset action, daily dosing, gastrointestinal side effects, and potential for exacerbation intestinal inflammation. Intravenous sucrose (IS) an effective safe alternative adults with IBD, but role IBD unclear. primary aim this study was to evaluate use IS patients determine clinical response measured...
Abstract Background Prospective long-term data on vedolizumab (VDZ) in children with Crohn’s disease (CD) and ulcerative colitis (UC) are lacking. In this prospective, multicenter cohort study, we aimed to evaluate the effectiveness safety of maintenance therapy VDZ pediatric CD UC. Methods Children commenced were followed at baseline 2, 6, 14, 30 54 weeks thereafter. Serum for drug levels stool calprotectin repeatedly obtained. The primary outcome was sustained steroid-free remission...